Featured News

9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

The NIH Accelerating Progress in Celiac Disease Workshop is a direct outcome of our advocacy efforts in Washington, DC. CEO Marilyn Geller was invited to speak about what our celiac community needs. Watch her presentation here.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

We are pleased to share that CEO Marilyn Geller will be presenting as the Patient Advocate at the March 18-19 National Institute of Allergy and Infectious Diseases Accelerating Progress in Celiac Disease Workshop. We encourage you to register to attend this seminal virtual meeting.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Society for the Study of Celiac Disease (SSCD) has released a statement on the COVID-19 vaccination and its safety for celiac disease patients.

A new study suggests a high dose of gluten might protect infants from celiac disease. However, other experts warn that the evidence shows a benefit only for introducing normal amounts of wheat to breastfed babies 4-6 months old.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

Celiac Disease Foundation Young Investigator Award recipient Jocelyn Silvester, MD, publishes “A new diagnostic paradigm for celiac disease.”